Group 1: Collaboration and Research Development - The company collaborates with China Pharmaceutical University to establish a joint laboratory focused on innovative and generic drug development, aiming to enhance the scientific reliability and authority of new drug research [2] - The joint laboratory is currently in the early stages of drug screening and optimization, working on clinical candidate discovery and the establishment of an in vitro bioactivity evaluation platform [2] Group 2: Clinical Trials and Drug Development - The company is conducting Phase IIa clinical trials for the drug Paenagabin, with 70 cases enrolled in Phase Ia and 20 cases in Phase Ib [4] - Paenagabin is positioned as a me-better drug compared to Retigabine, which was withdrawn from the market due to stability and safety issues; Paenagabin shows higher activity and better distribution in the brain [3] - The company plans to expand the indications for Paenagabin based on Phase II clinical results and market demand, potentially including severe depression caused by KCNQ mutations [3][4] Group 3: Future Prospects and Market Strategy - The company anticipates entering Phase III clinical trials for the drug Fluorofenidone in the second half of 2025, which has been included in the list of breakthrough therapies by the National Medical Products Administration [5] - Fluorofenidone is expected to expand its indications to include patients with liver fibrosis caused by metabolic liver diseases, depending on clinical trial outcomes [5][6] Group 4: Shareholder Information - The reduction of shares by Yunnan International Trust is a passive action based on prior agreements and will not affect the company's long-term operations and development [6]

Group 1 - 华夏基金 announced the opening of its 华夏安泰对冲策略3个月定期开放灵活配置混合基金 for subscription, redemption, and conversion from May 16 to May 22, 2025, with a total scale limit of 2.3 billion yuan [1] - The 华夏安泰对冲策略3个月定开基金 has achieved a cumulative net value growth rate of 23.28% and an annualized return of 4.33% since its establishment in June 2020, ranking first among similar products [1] - The fund's scale has been continuously growing since Q2 2023, reaching 2.304 billion yuan in mid-2024, and has implemented scale control measures since the open period in August 2023 [1] Group 2 - The average return rate for 42 hedge strategy funds in the market as of May 12 is 0.85%, with 80% of products achieving positive returns, and the best-performing funds exceeding a 3% return [2] - The total scale of hedge strategy funds in the market has declined recently, with a total scale of less than 5.5 billion yuan as of Q1 2025, a decrease of nearly 20% compared to the end of last year and over 35% compared to mid-last year [2] - The scale control mechanism implemented by funds is believed to help maintain operational stability and provide a better investment experience for holders [1]

Report Industry Investment Rating There is no information provided in the report regarding the industry investment rating. Core Viewpoints - On May 13, 2025, the Shanghai Composite Index rose 0.17% to 3374.87 points, the Shenzhen Component Index fell 0.13% to 10288.08 points, and the ChiNext Index fell 0.12% to 2062.26 points. The total trading volume of A-shares in the two markets was 1325.1 billion yuan. The top-performing industries were banking (1.52%), beauty and care (1.18%), and pharmaceutical biology (0.90%), while the worst-performing industries were national defense and military industry (-3.07%), computer (-0.80%), and machinery and equipment (-0.66%) [2][6]. Summary by Directory Market Overview - The Shanghai Composite Index rose 0.17%, the Shenzhen Component Index fell 0.13%, and the ChiNext Index fell 0.12%. The total trading volume of A-shares in the two markets was 1325.1 billion yuan. The top-performing industries were banking, beauty and care, and pharmaceutical biology, while the worst-performing industries were national defense and military industry, computer, and machinery and equipment [2][6]. Stock ETF - The top trading volume stock ETFs were Huaxia CSI A500 ETF (up 0.11% with a premium rate of 0.08%), Huatai-PineBridge CSI 300 ETF (up 0.10% with a premium rate of 0.08%), and Guotai CSI A500 ETF (unchanged with a premium rate of -0.01%) [3][7]. Bond ETF - The top trading volume bond ETFs were Fuguo ChinaBond 7 - 10 Year Policy Financial Bond ETF (down 0.13% with a premium rate of 0.15%), Pengyang ChinaBond - 30 Year Treasury Bond ETF (down 0.38% with a premium rate of 0.52%), and Haifutong CSI Short - Term Commercial Paper ETF (unchanged with a premium rate of -0.00%) [4][9]. Gold ETF - The price of gold AU9999 rose 0.65%, and Shanghai Gold fell 0.31%. The top trading volume gold ETFs were Huaan Gold ETF (down 0.60% with a premium rate of 0.67%), E Fund Gold ETF (down 0.59% with a premium rate of 0.65%), and Bosera Gold ETF (down 0.61% with a premium rate of 0.65%) [12]. Commodity Futures ETF - Huaxia Feed Soybean Meal Futures ETF fell 0.21% with a premium rate of 1.54%, Dacheng Non - Ferrous Metals Futures ETF fell 0.12% with a premium rate of 0.14%, and Jianxin Yisheng Zhengzhou Commodity Exchange Energy and Chemical Futures ETF rose 0.77% with a premium rate of 1.75% [13]. Cross - Border ETF - The previous trading day, the Dow Jones Industrial Average rose 2.81%, the Nasdaq Composite rose 4.35%, the S&P 500 rose 3.26%, and the German DAX rose 0.29%. On this day, the Hang Seng Index fell 1.87%, and the Hang Seng China Enterprises Index fell 2.02%. The top trading volume cross - border ETFs were Huaxia Hang Seng Tech ETF (down 0.83% with a premium rate of -3.43%), Huatai - PineBridge Southern Dongying Hang Seng Tech ETF (down 0.84% with a premium rate of -3.33%), and Guotai S&P 500 ETF (up 10.01% with a premium rate of 23.45%) [15]. Money ETF - The top trading volume money ETFs were Yin Hua Ri Li ETF, Hua Bao Tian Yi ETF, and Money ETF Jian Xin Tian Yi [17].

Group 1 - Public fund institutions remained active in research activities, with 146 institutions participating in A-share company research from May 5 to May 11, covering 156 stocks across 24 industries, totaling 1198 research instances [1][2] - The mechanical equipment sector stood out, with LeiSai Intelligent (002979) leading with 54 research instances, attracting nearly 30% of public institutions, while Honghua Digital Technology also received 33 instances [1][2] - The pharmaceutical and biological industry was another focus, with three stocks in the top ten, including Baiji Shenzhou, YiHe JiaYe (301367), and AoHua Endoscopy, receiving 49, 44, and 35 research instances respectively, indicating strong market interest in innovative drugs and medical devices [1][2] Group 2 - The electronic, pharmaceutical, and mechanical equipment sectors were the main areas of focus for public fund research, with electronic industry leading at 201 instances, followed by pharmaceutical at 194, and mechanical equipment at 143 [2] - A significant concentration of research activity was noted, with over 60% of public institutions conducting more than four research activities, and nine leading institutions exceeding 20 research instances [2][3] - Among the top ten active public institutions, Penghua Fund Management conducted 28 research instances, focusing on stocks like Naer Shares (002825), Oulutong (300870), and Honghua Digital Technology, which had notable weekly gains [3]

Core Viewpoint - China Duty Free Group Co., Ltd. (formerly known as China National Travel Service Group Corporation) has experienced a decline in stock price over four consecutive trading days, with a cumulative drop of -1.56% [1] Company Overview - China Duty Free Group is a large joint-stock enterprise focused on tourism retail, controlled by China Tourism Group Co., Ltd. [1] - The company is listed and is one of the major players in the tourism retail sector in China [1] Financial Performance - In the first quarter of this year, the Invesco Great Wall New Emerging Growth Mixed A fund remains one of the top ten shareholders of China Duty Free, with a year-to-date return of -0.17%, ranking 3010 out of 4581 in its category [1][2] - The fund's performance over various time frames shows a near-term increase of 1.10% over the past week, but a decline of -0.23% over the past month and -8.83% over the past six months [2] Fund Management - The fund manager, Liu Yanchun, has a management experience of over 16 years and has held various positions in different financial institutions before joining Invesco Great Wall in January 2015 [3][4] - Liu Yanchun is currently managing multiple funds, including the Invesco Great Wall New Emerging Growth Mixed Fund and others, with a total fund size of 410.20 billion yuan and a cumulative return of 162.55% [4]

Group 1 - The core investment strategy focuses on buying companies with competitive advantages at reasonable prices to earn compounded growth, emphasizing strong business models and financial robustness [1][8] - The growth value fund pool has shown a stable annualized return of 15.74% from February 2, 2015, to May 8, 2025, outperforming the equity fund index by 9.23% [9][13] - The fund pool's annualized volatility is 20.98%, with a Sharpe ratio of 0.75, indicating strong performance in bull markets and effective drawdown control in bear markets [9][13] Group 2 - The primary source of excess returns is stock selection, with significant contributions from industry allocation and dynamic adjustments [2][13] - The growth value fund pool is defined by its relative undervaluation characteristics, focusing on funds with positive exposure to the PB-ROE factor [21] - Selected funds exhibit high and stable dynamic returns, with a focus on industry and stock selection [22] Group 3 - The report lists a new growth value fund portfolio, highlighting funds such as "Guangfa Value Core A" with a return of 27.79% and "Invesco Financial Industry A" with a return of 5.32% [3][22] - The fund pool has increased its allocation to the TMT sector while reducing exposure to consumer and cyclical sectors [18][15] - The report emphasizes the importance of matching individual company performance with industry trends for effective stock selection [25]

| 13:51 | 销售机构全称 | 销售机构设应 | | --- | --- | --- | | T | 中国米大银行股份有限公司 | 注册地址,北京市西城区太平衡人面25号元大中心 | | | | 办公地址:全系市西城区太平街大街25号光大中心 | | | | 法定代表人r EII. | | | | SSLink VITE BEER (AD) Milli www.cebbank.com | | 2 | 图解图有载 图书馆公司 | 在国家的城市: 8000 国家 国家 1000 2008 2 186 法定代表人:都是民 | | | | 名户服务电话,96655 | | | | mode www.ombchina.com | | 3 | 形酸银行散约在限公可相量增 | moos sningchina.com | | | | 天都市行 188588 | | 4 | 菜体都已吸得到面的可能面去之一和财经 文昌平台" | 发出版及电影,第一次 | | | | Milli www.alb.com.on in in https/ / f.aib.com.cn | | રિ | 平安银行打E通平台 | 在周(外公)意见》 ...

为更好地满足广大投资者的理财需求，根据景顺长城基金管理有限公司（以下简称"本公司"）与上海银 行股份有限公司（以下简称"上海银行"）签署的委托销售协议，自2025年5月12日起新增委托上海银行 销售景顺长城中证A500交易型开放式指数证券投资基金联接基金Y类基金份额，具体的业务流程、办理 时间和办理方式以上海银行的规定为准。现将相关事项公告如下： 一、适用基金及基金业务开通情况 ■ 注：本公司新增委托上海银行销售上述列表中对应基金，上表仅就基金本身是否开通定期定额投资、转 换业务和是否参加销售机构申购（含定期定额申购）费率优惠进行说明，投资者能否通过上述销售机构 办理基金上述业务，以上述销售机构的安排和规定为准。 二、销售机构信息 销售机构全称：上海银行股份有限公司 注册地址：上海市黄浦区中山南路688号 办公地址：上海市黄浦区中山南路688号 法定代表人：金煜 客户服务电话：95594 网址：http://www.bosc.cn/ 三、相关业务说明 1、上述申购赎回等业务仅适用于处于正常申购期及处于特定开放日和开放时间的基金。基金封闭期、 募集期等特殊期间的有关规定详见对应基金的《基金合同》、《招募说明书》 ...

Core Viewpoint - The AI Fund, Invesco Great Wall Quality Investment Mixed A, reported a profit of 20.4353 million yuan for Q1 2025, with a weighted average profit per fund share of 0.1458 yuan, and a net value growth rate of 4.81% during the reporting period [3][15]. Fund Performance - As of April 24, the fund's unit net value was 2.982 yuan, with a fund size of 438 million yuan [3][15]. - The fund's performance over different time frames includes a three-month net value growth rate of -2.55%, a six-month rate of -1.91%, a one-year rate of 12.53%, and a three-year rate of -3.40% [4]. - The fund's Sharpe ratio over the past three years is 0.1834, ranking 194 out of 488 comparable funds [9]. - The maximum drawdown over the past three years is 36.63%, with the largest single-quarter drawdown occurring in Q1 2024 at 23.54% [11]. Investment Strategy - The fund manager emphasizes a focus on three main investment directions for the next 5-10 years: 1. **Technology Growth**: Investing in companies capable of breakthroughs in high-end manufacturing, supported by policy initiatives [3]. 2. **High-end Manufacturing**: Identifying investment opportunities in sectors that can achieve self-sufficiency and import substitution [3]. 3. **Pharmaceuticals**: Targeting companies that will benefit from aging populations and innovation upgrades, with strong long-term performance potential [3]. Portfolio Composition - As of Q1 2025, the fund's top ten holdings include Ningde Times, Ninebot, Zijin Mining, Midea Group, Luxshare Precision, New Industry, SiTewi, Anji Technology, BYD, and Sankeshu [18]. Fund Positioning - The fund's average stock position over the past three years is 85.44%, slightly above the comparable average of 85.26% [14].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 为更好地满足广大投资者的理财需求，根据景顺长城基金管理有限公司（以下简称"本公司"）与开源证 券股份有限公司（以下简称"开源证券"）签署的委托销售协议，自2025年5月7日起新增委托开源证券销 售本公司旗下部分基金，具体的业务流程、办理时间和办理方式以开源证券的规定为准。现将相关事项 公告如下： 一、适用基金及基金业务开通情况 联系人：杨淑涵 电话：15809201060 客户服务电话：95325 ■ 注：本公司新增委托开源证券销售上述列表中对应基金，上表仅就基金本身是否开通定期定额投资、转 换业务和是否参加销售机构申购（含定期定额申购）费率优惠进行说明，投资者能否通过上述销售机构 办理基金上述业务，以上述销售机构的安排和规定为准。 二、销售机构信息 销售机构名称：开源证券股份有限公司 注册地址：西安市高新区锦业路1号都市之门B座5层 办公地址：西安市高新区锦业路1号都市之门B座5层 法定代表人：李刚 网址：www.kysec.cn 三、相关业务说明 1、上述申购赎回等业务仅适用于处于正常申购期及处于特定开放日和开放时间的基金。基金封闭 ...